Host Genetic Factors Determining COVID-19 Susceptibility and Severity

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2021 Oct 16

PMID 34655949

Citations 111

Authors

Thirumalaisamy P Velavan

Srinivas Reddy Pallerla

Jule Ruter

Yolanda Augustin

Peter G Kremsner

Sanjeev Krishna

Christian G Meyer

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) poses an unprecedented challenge to humanity. SARS-CoV-2 infections range from asymptomatic to severe courses of COVID-19 with acute respiratory distress syndrome (ARDS), multiorgan involvement and death. Risk factors for disease severity include older age, male sex, increased BMI and pre-existing comorbidities. Ethnicity is also relevant to COVID-19 susceptibility and severity. Host genetic predisposition to COVID-19 is now increasingly recognized and whole genome and candidate gene association studies regarding COVID-19 susceptibility have been performed. Several common and rare variants in genes related to inflammation or immune responses have been identified. We summarize research on COVID-19 host genetics and compile genetic variants associated with susceptibility to COVID-19 and disease severity. We discuss candidate genes that should be investigated further to understand such associations and provide insights relevant to pathogenesis, risk classification, therapy response, precision medicine, and drug repurposing.

Citing Articles

Case-control association study between polygenic risk score and COVID-19 severity in a Russian population using low-pass genome sequencing.

Nostaeva A, Shimansky V, Apalko S, Kuznetsov I, Sushentseva N, Popov O Epidemiol Infect. 2024; 153():e13.

PMID: 39721951 PMC: 11748017. DOI: 10.1017/S0950268824001778.

Association study of the JAK/STAT signaling pathway with susceptibility to COVID-19 in moroccan patient and in-silico analysis of rare variants.

El Houdi M, Skhoun H, El Fessikh M, Benmansour R, El Yousfi F, Nebhani C Virus Res. 2024; 351():199509.

PMID: 39647533 PMC: 11699608. DOI: 10.1016/j.virusres.2024.199509.

Correlation between rs7041 and rs4588 polymorphisms in vitamin D binding protein gene and COVID-19-related severity and mortality.

Hamed E, Abdelhady S, Al-Touny S, Kishk R, Mohamed M, Rageh F BMC Med Genomics. 2024; 17(1):284.

PMID: 39623417 PMC: 11613538. DOI: 10.1186/s12920-024-02018-y.

Integrative multi-omics analysis to gain new insights into COVID-19.

Eshetie S, Choi K, Hypponen E, Benyamin B, Lee S Sci Rep. 2024; 14(1):29803.

PMID: 39616224 PMC: 11608341. DOI: 10.1038/s41598-024-79904-z.

MDA5 Is a Major Determinant of Developing Symptoms in Critically Ill COVID-19 Patients.

Maiti A Clin Rev Allergy Immunol. 2024; 67(1-3):58-72.

PMID: 39460899 DOI: 10.1007/s12016-024-09008-z.

References

Vietzen H, Zoufaly A, Traugott M, Aberle J, Aberle S, Puchhammer-Stockl E . Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19. Genet Med. 2021; 23(5):963-967. PMC: 7835668. DOI: 10.1038/s41436-020-01077-7. View

Ceccaldi P, Delebecque F, Prevost M, Moris A, Abastado J, Gessain A . DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells. J Virol. 2006; 80(10):4771-80. PMC: 1472089. DOI: 10.1128/JVI.80.10.4771-4780.2006. View

Fajgenbaum D, June C . Cytokine Storm. N Engl J Med. 2020; 383(23):2255-2273. PMC: 7727315. DOI: 10.1056/NEJMra2026131. View

Deng Q, Rasool R, Russell R, Natesan R, Asangani I . Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience. 2021; 24(3):102254. PMC: 7919514. DOI: 10.1016/j.isci.2021.102254. View

Novick D, Cohen B, Rubinstein M . The human interferon alpha/beta receptor: characterization and molecular cloning. Cell. 1994; 77(3):391-400. DOI: 10.1016/0092-8674(94)90154-6. View

Lee N, Chan K, Hui D, Ng E, Wu A, Chiu R . Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31(4):304-9. PMC: 7108318. DOI: 10.1016/j.jcv.2004.07.006. View

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

Picchiotti N, Salvioli M, Zanardini E, Missale F . COVID-19 pandemic: a mobility-dependent SEIR model with undetected cases in Italy, Europe, and US. Epidemiol Prev. 2021; 44(5-6 Suppl 2):136-143. DOI: 10.19191/EP20.5-6.S2.112. View

Zhu J, Wu C, Wu L . Associations Between Genetically Predicted Protein Levels and COVID-19 Severity. J Infect Dis. 2020; 223(1):19-22. PMC: 7797748. DOI: 10.1093/infdis/jiaa660. View

10.

Ching J, Chan K, Lee E, Xu M, Ting C, So T . Significance of the myxovirus resistance A (MxA) gene -123C>a single-nucleotide polymorphism in suppressed interferon beta induction of severe acute respiratory syndrome coronavirus infection. J Infect Dis. 2010; 201(12):1899-908. PMC: 7109798. DOI: 10.1086/652799. View

11.

Gerard C, Maggipinto G, Minon J . COVID-19 and ABO blood group: another viewpoint. Br J Haematol. 2020; 190(2):e93-e94. PMC: 7283642. DOI: 10.1111/bjh.16884. View

12.

Nguyen A, David J, Maden S, Wood M, Weeder B, Nellore A . Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. J Virol. 2020; 94(13). PMC: 7307149. DOI: 10.1128/JVI.00510-20. View

13.

Mudd P, Crawford J, Turner J, Souquette A, Reynolds D, Bender D . Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv. 2020; 6(50). PMC: 7725462. DOI: 10.1126/sciadv.abe3024. View

14.

Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P . Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020; 383(16):1522-1534. PMC: 7315890. DOI: 10.1056/NEJMoa2020283. View

15.

Li F, Han M, Dai P, Xu W, He J, Tao X . Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021; 12(1):866. PMC: 7870838. DOI: 10.1038/s41467-021-21171-x. View

16.

Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

17.

Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U . Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis. J Clin Immunol. 2020; 41(1):11-22. PMC: 7602765. DOI: 10.1007/s10875-020-00899-z. View

18.

Bakhshandeh B, Sorboni S, Javanmard A, Mottaghi S, Mehrabi M, Sorouri F . Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect Genet Evol. 2021; 90:104773. PMC: 7886638. DOI: 10.1016/j.meegid.2021.104773. View

19.

Manichaikul A, Wang X, Sun L, Dupuis J, Borczuk A, Nguyen J . Genome-wide association study of subclinical interstitial lung disease in MESA. Respir Res. 2017; 18(1):97. PMC: 5437638. DOI: 10.1186/s12931-017-0581-2. View

20.

Boutin S, Hildebrand D, Boulant S, Kreuter M, Ruter J, Pallerla S . Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs. Cell Mol Life Sci. 2021; 78(16):5953-5976. PMC: 8256233. DOI: 10.1007/s00018-021-03889-5. View